Hetlioz (Tasimelteon) Patent Expiration, LOE Window & CMS Spending

Hetlioz (Tasimelteon) by Vanda: FDA Orange Book core substance LOE 2035-02-12 (last listed 2041-02-21), 3 AB generics, $82.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorVanda
FDA Application & PathwayN205677 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2035-02-12
Last Listed Patent or Exclusivity Date2041-02-21
Orange Book Patents (*PED Extensions)31 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$82.7M
2024 Medicare Part D Spend$65.3M
2024 Medicaid Spend$17.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel